To our knowledge, this study is the first to demonstrate that high expression of TRAIL-R3 and CCR-2 in TEpCs serves as a prognostic marker of metastatic tumors as well as DFS, MFS, and OS in women with stage I/II invasive breast cancer. This evidence concerns the gene TNFRSF10C and metastatic neoplasm.